2BBBullish & Bearish
Amylyx Pharmaceuticals, Inc. (AMLX) trades on NASDAQ. It operates in the Health Care sector, Drug Manufacturers - Specialty & Generic industry. Its current 2BB score is 40 out of 100.
Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. It was withdrawn in April, 2024.
Amylyx Pharmaceuticals, Inc.’s current 2BB score is 40 out of 100, built from the signal categories below.
| Signal | Score | Reading |
|---|---|---|
| Activity | 62 | High |
| Momentum | 54 | Stable |
| Financial strength | 13 | Very Weak |
| Quality | 100 | Very Strong |
| Risk | 40 | Low |
| Founded | 2013 |
| Employees | 136 |
| 52-week range | $7.63 – $24.60 |
| Report date | EPS actual | EPS estimate | Revenue actual | Revenue estimate |
|---|---|---|---|---|
| 2026-11-04 | — | -0.3865 | — | $0.00 |
| 2026-08-06 | — | -0.3681 | — | $0.00 |
| 2026-05-07 | -0.37 | -0.3369 | $0.00 | $0.00 |
| 2026-03-03 | -0.3 | -0.366 | $0.00 | $0.00 |